RayKnowChina Research Map
Shortlist

ZhengzhouZhengzhou University

Henan Provincial People's Hospital

河南省人民医院

Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Henan Provincial People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌20 papers led
  3. Hepatocellular carcinoma肝细胞癌30 papers led
  4. Stomach cancer胃癌25 papers led
  5. Retinoblastoma视网膜母细胞瘤2 papers led
  6. Chordoma脊索瘤0 papers led
  7. Osteosarcoma骨肉瘤7 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  9. Neuroblastoma神经母细胞瘤3 papers led
  10. Ewing sarcoma尤文肉瘤0 papers led
  11. Multiple myeloma多发性骨髓瘤5 papers led
  12. Haemophilia A血友病 A2 papers led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  14. Fanconi anaemia范可尼贫血1 paper led
  15. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  16. Myasthenia gravis重症肌无力2 papers led
  17. Moyamoya disease烟雾病5 papers led
  18. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  19. Takayasu arteritis大动脉炎0 papers led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化5 papers led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  22. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  23. IgA nephropathyIgA 肾病1 paper led
  24. Osteogenesis imperfecta成骨不全症0 papers led
  25. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  26. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  27. Inherited epidermolysis bullosa遗传性大疱性表皮松解症2 papers led
  28. Hereditary angioedema遗传性血管性水肿0 papers led
  29. Leber hereditary optic neuropathyLeber 遗传性视神经病变3 papers led

Not listed for: Hepatoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, IgG4-related disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

4 hospitals in Zhengzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyEBV & screening
Departments in papersENT / head & neck surgeryMedical oncology
Papers it led3
  1. miR-34c-3p Inhibits Nasopharyngeal Carcinoma Development via Inhibiting M2 Polarization of Macrophages.2025Biomedical and environmental sciences : BES
  2. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.2023Frontiers in immunologyFree full text
  3. Hsa_circ_0000345 inhibits cell proliferation, migration and invasion of nasopharyngeal carcinoma cells via miR-513a-3p/PTEN axis.2022The journal of physiological sciences : JPSFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Intermittent Oro-esophageal Tube Feeding in Late Dysphagia for Nasopharyngeal CarcinomaWithdrawnNCT06248879Lead sponsorN/AStart 2024-02
More papers found outside PubMed (not counted)10
  1. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  2. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  3. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  4. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  5. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  6. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  7. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  8. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  9. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  10. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 20 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 4420232024: 5520242025: 442025

6 hospitals in Zhengzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapyEarly detection & endoscopy
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led20
  1. Biocompatible hydrogel co-delivering salvigenin and iridium (III) complex overcomes cancer stemness and cisplatin resistance in esophageal squamous cell carcinoma.2026Colloids and surfaces. B, Biointerfaces
  2. Multi-omics analysis unveils a four-gene prognostic signature in esophageal squamous carcinoma and the therapeutic potential of PKP1.2025BMC cancerFree full text
  3. Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study.2025Frontiers in immunologyFree full text
  4. METTL3-Mediated m6A Methylation Stabilizes IFI27 to Drive Esophageal Squamous Cell Carcinoma Progression Through an IGF2BP2-Dependent Mechanism.2025Journal of biochemical and molecular toxicology
  5. Screening, Validation, and Machine Learning-Based Evaluation of Serum Protein Biomarkers for Esophageal Squamous Cell Carcinoma Based on Single-Cell Subtype-Specific Genes.2025Journal of proteome research
  6. Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula.2024Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  7. Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling.2024Cancer biology & therapyFree full text
  8. DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3.2024Journal of translational medicineFree full text
  9. EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment.2024Pharmacological research
  10. The anti-tumor activity of tangeretin in esophageal squamous cell carcinoma by inhibiting GLI2-mediated transcription of GPNMB.2024PloS oneFree full text
  11. LincRNA-P21 knockdown facilitates esophageal squamous cell carcinoma cell progression by upregulating cadherin 5 via YTH domain containing 1.2023Acta biochimica et biophysica SinicaFree full text
  12. Exosomal circ_0026611 contributes to lymphangiogenesis by reducing PROX1 acetylation and ubiquitination in human lymphatic endothelial cells (HLECs).2023Cellular & molecular biology lettersFree full text
  13. Hsa_circ_0046534 accelerates esophageal squamous cell carcinoma proliferation and metastasis via regulating MMP2 expression by sponging miR-339-5p.2023Cellular signalling
  14. The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma.2023MedicineFree full text
  15. DNA methyltransferase 3 beta regulates promoter methylation of microRNA-149 to augment esophageal squamous cell carcinoma development through the ring finger protein 2/Wnt/β-catenin axis.2022BioengineeredFree full text
  16. HA-ADT suppresses esophageal squamous cell carcinoma progression via apoptosis promotion and autophagy inhibition.2022Experimental cell research
  17. Identification of a novel circ_0001946/miR-1290/SOX6 ceRNA network in esophageal squamous cell cancer.2022Thoracic cancerFree full text
  18. Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma.2021BMC microbiologyFree full text
  19. RELT promotes the growth of esophageal squamous cell carcinoma by activating the NF-κB pathway.2021Cell cycle (Georgetown, Tex.)Free full text
  20. TMEM161B-AS1 suppresses proliferation, invasion and glycolysis by targeting miR-23a-3p/HIF1AN signal axis in oesophageal squamous cell carcinoma.2021Journal of cellular and molecular medicineFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Study siteStart 2022-07
  2. TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Study sitePhase 2Start 2021-09
  3. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)9
  1. 2119P Perioperative study of BTLA combined with PD-1 and chemotherapy as bispecific immunosuppressants for resectable thoracic esophageal squamous cell carcinoma (BT-NICE trial): A prospective, single group, phase II study2025Annals of Oncologyarticle
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Encouraging efficacy of sintilimab combined with nanoparticle albumin-bound paclitaxel and platinum as the first-line treatment for metastatic esophageal squamous cell carcinoma: A retrospective study.2022Journal of Clinical Oncologyconference-abstract
  7. Preliminary study on the role and mechanism of KIRREL3 in the development of esophageal squamous cell carcinoma (ESCC)2022Research Squarepreprint
  8. LRP16 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Regulating Hippo Signaling Pathway2021Research Squarepreprint
  9. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 30 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
30
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 7720212022: 7720222023: 2220232024: 3320242025: 10102025

3 hospitals in Zhengzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionHepatitis B & cirrhosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led30
  1. WTAP contributes to the malignancy and stemness of hepatocellular carcinoma through upregulating N6-methyladenosine modification of ITGB4.2026Pathology, research and practice
  2. Value of Abbreviated Magnetic Resonance Sequence in Hepatocellular Carcinoma Screening: A Systematic Review and Meta-analysis.2025Academic radiology
  3. HLA-DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T-Cell Exhaustion in HBV-Associated Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Imaging-Based Prediction of Ki-67 Expression in Hepatocellular Carcinoma: A Retrospective Study.2025Cancer medicineFree full text
  5. Multi-omics spatial characteristics of CD8+TRM cells in hepatocellular carcinoma and immunotherapy response prediction.2025Frontiers in immunologyFree full text
  6. The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  7. Integrated bioinformatics and in vitro validation reveal TUBB as a core gene and therapeutic target in NAFLD-related hepatocellular carcinoma.2025International journal of biological macromolecules
  8. Increased expression of DNAJC7 promotes the progression of hepatocellular carcinoma by influencing the cell cycle and immune microenvironment.2025Journal of cancer research and clinical oncologyFree full text
  9. FAIM modulates HCC progression via enhancing HMGA1 interaction with CDK7 and promoting its phosphorylation level.2025Journal of translational medicineFree full text
  10. Transcriptional regulation of tumor suppressor gene RASSF1A by HBx.2025Molecular and cellular probes
  11. OTUD7B is a new deubiquitinase targeting p53.2025TheranosticsFree full text
  12. Proteo-genomic characterization of cirrhosis-associated liver cancers reveals potential subtypes and therapeutic targets.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  13. Myocardial and Cerebral Infarction after Transarterial Bland Microsphere Embolization for Hepatocellular Carcinoma: A Case Report.2024Journal of vascular and interventional radiology : JVIR
  14. TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3.2024Scientific reportsFree full text
  15. LncRNA RP11-620J15.3 promotes HCC cell proliferation and metastasis by targeting miR-326/GPI to enhance glycolysis.2023Biology directFree full text
  16. Noninvasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics: A Multicenter Study.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  17. Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling.2022BioengineeredFree full text
  18. LINC01419 Promotes the Proliferation of Hepatoma Cells by Recruiting XRCC5 and Regulating Its Phosphorylation to Repair DNA Damage.2022Disease markersFree full text
  19. Hydroxyacid Oxidase 2 (HAO2) Inhibits the Tumorigenicity of Hepatocellular Carcinoma and Is Negatively Regulated by miR-615-5p.2022Journal of immunology researchFree full text
  20. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma.2022Laboratory investigation; a journal of technical methods and pathology
  21. The long non-coding RNA LIMT inhibits metastasis of hepatocellular carcinoma and is suppressed by EGF signaling.2022Molecular biology reportsFree full text
  22. Sarcopenia as an Independent Risk Factor for Specific Cancers: A Propensity Score-Matched Asian Population-Based Cohort Study.2022NutrientsFree full text
  23. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation.2022Pharmaceutical biologyFree full text
  24. Evaluation of Glypican-3 Expression in Hepatocellular Carcinoma by Using IDEAL IQ Magnetic Resonance Imaging.2021Academic radiology
  25. miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.2021Biochemical and biophysical research communications
  26. Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets.2021BioengineeredFree full text
  27. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data.2021British journal of cancerFree full text
  28. ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway.2021Cell cycle (Georgetown, Tex.)Free full text
  29. Hybrid network with difference degree and attention mechanism combined with radiomics (H-DARnet) for MVI prediction in HCC.2021Magnetic resonance imaging
  30. CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis.2021Scientific reportsFree full text
Chinese-language papers (not in the count)2
  1. [Circ_0026134 regulates the miR-1270/GRB2 pathway to affect the radiosensitivity of hepatoma cells].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Problems and pitfalls of the hepatocyte-specific contrast agent gadoxetate disodium for assessing the main criteria of LI-RADS version 2018].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  2. A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)Status unknownNCT06023147Study siteN/AStart 2023-09
  3. Nurse-led Decision Counseling on Hepatocellular Carcinoma ScreeningCompletedNCT04659005Study siteN/AStart 2021-02
  4. Autologous CAR-T/TCR-T Cell Immunotherapy for Solid MalignanciesStatus unknownNCT03941626Study sitePhase 1/Phase 2Start 2019-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 25 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 8820222023: 1120232024: 6620242025: 332025

4 hospitals in Zhengzhou for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseImaging & AI
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineMedical oncology
Papers it led25
  1. Spatial transcriptomic characteristics of gastric cancer in young and the expression and role of TMEM176B in gastric cancer cells.2025European journal of medical researchFree full text
  2. Global Prevalence of Helicobacter pylori Infection-Associated Gastric Preneoplastic Lesions in Pediatric Patients: A Systematic Review and Meta-Analysis.2025Helicobacter
  3. An interpretable hybrid deep learning framework for gastric cancer diagnosis using histopathological imaging.2025Scientific reportsFree full text
  4. The three-stage and seven-step method for laparoscopic radical gastrectomy: A new surgical procedure for gastric cancer.2024Asian journal of surgery
  5. Pathological complete remission (PCR) in a patient with unresectable gastric cancer undergoing preoperative conversion therapy.2024Asian journal of surgery
  6. Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.2024Helicobacter
  7. Benzimidazole-based structure optimization to discover novel anti-gastric cancer agents targeting ROS/MAPK pathway.2024Journal of biochemical and molecular toxicology
  8. Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer.2024Postgraduate medical journal
  9. Comprehensive analysis of risk factors associated with submucosal invasion in patients with early-stage gastric cancer.2024World journal of gastroenterologyFree full text
  10. Relationship between the number of dissected lymph node and the pathological staging in esophagogastric junction adenocarcinoma.2023Asian journal of surgery
  11. Identification of a seven-cell cycle signature predicting overall survival for gastric cancer.2022AgingFree full text
  12. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.2022Disease markersFree full text
  13. Non-invasive measurement of tumor immune microenvironment and prediction of survival and chemotherapeutic benefits from 18F fluorodeoxyglucose PET/CT images in gastric cancer.2022Frontiers in immunologyFree full text
  14. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.2022Helicobacter
  15. "Two-Side Approach, Four-Step Dissociation" Surgical Technique for Splenic Hilar Lymphadenectomy During Laparoscopic Total Gastrectomy for Advanced Gastric Cancer.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  16. Plasma Exosomal hsa_circ_0015286 as a Potential Diagnostic and Prognostic Biomarker for Gastric Cancer.2022Pathology oncology research : PORFree full text
  17. Family-based Helicobacter pylori infection status and transmission pattern in central China, and its clinical implications for related disease prevention.2022World journal of gastroenterologyFree full text
  18. Gastric mucosal precancerous lesions in Helicobacter pylori-infected pediatric patients in central China: A single-center, retrospective investigation.2022World journal of gastroenterologyFree full text
  19. Knockdown of hsa_circ_0091994 constrains gastric cancer progression by suppressing the miR-324-5p/HMGA1 axis.2021AgingFree full text
  20. A novel circular RNA circ_HN1/miR-628-5p/Ecto-5'-nucleotidase competing endogenous RNA network regulates gastric cancer development.2021BioengineeredFree full text
  21. Tissue-based metabolomics reveals metabolic signatures and major metabolic pathways of gastric cancer with help of transcriptomic data from TCGA.2021Bioscience reportsFree full text
  22. CDC42EP3 is a key promoter involved in the development and progression of gastric cancer.2021Carcinogenesis
  23. m6 A transferase KIAA1429-stabilized LINC00958 accelerates gastric cancer aerobic glycolysis through targeting GLUT1.2021IUBMB life
  24. Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells.2021Investigational new drugs
  25. STROBE-clinical characteristics and prognosis factors of gastric cancer in young patients aged ≤30 years.2021MedicineFree full text
Chinese-language papers (not in the count)1
  1. [Application of 3D-CT simulation image in the description of gastric artery variation to guide laparoscopic total gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status6
  1. HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk PatientsStatus unknownNCT05510388Study siteN/AStart 2022-09
  2. Nasal Mask Kit in Gastrointestinal EndoscopyCompletedNCT05405530Study siteN/AStart 2022-09
  3. Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly PatientsCompletedNCT05030870Study siteN/AStart 2021-09
  4. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  5. Autologous CAR-T/TCR-T Cell Immunotherapy for Solid MalignanciesStatus unknownNCT03941626Study sitePhase 1/Phase 2Start 2019-09
  6. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Zhengzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Zhengzhou for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Chondromucinous tumors involving craniocerebral slope area: a clinicopathological analysis of eight cases].2019Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 1120242025: 222025

16 hospitals in Zhengzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led7
  1. Integrating single-cell transcriptomics, molecular docking, and dynamics simulations to characterize protein kinase X-linked mechanisms in osteosarcoma.2025International journal of biological macromolecules
  2. Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma.2025Scientific reports
  3. Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.2024Orthopaedic surgery
  4. DNMT1 determines osteosarcoma cell resistance to apoptosis by associatively modulating DNA and mRNA cytosine-5 methylation.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  5. Multiproperty Polyethylenimine-Caged Platinum Nanoclusters Promote Apoptosis of Osteosarcoma Cells via Regulating the BAX-Bcl-2/Caspase-3/PARP Axis.2023Molecular pharmaceutics
  6. Circular RNA circVRK1 suppresses the proliferation, migration and invasion of osteosarcoma cells by regulating zinc finger protein ZNF652 expression via microRNA miR-337-3p.2021Bioengineered
  7. Circ-XPR1 promotes osteosarcoma proliferation through regulating the miR-214-5p/DDX5 axis.2021Human cell
Chinese-language papers (not in the count)1
  1. [The expression of neuraminidase-1 in Ewing sarcoma and its impact on sarcoma cell proliferation and migration].2023Zhonghua yi xue za zhi
Earlier papers (2016–2020)5
  1. MicroRNA-765 targets MTUS1 to promote the progression of osteosarcoma via mediating ERK/EMT pathway.2019European review for medical and pharmacological sciences
  2. miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16.2019International journal of oncology
  3. G-protein-coupled estrogen receptor suppresses the migration of osteosarcoma cells via post-translational regulation of Snail.2019Journal of cancer research and clinical oncology
  4. LncRNA SNHG15 contributes to proliferation, invasion and autophagy in osteosarcoma cells by sponging miR-141.2017Journal of biomedical science
  5. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.2016Cancer investigation

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Zhengzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. Mutation of the KIT Gene, excluding Exon 11, in Gastrointestinal Stromal Tumors.2020Biomedical and environmental sciences : BES
  2. Analyzing the molecular mechanism of the tissue specificity of gastrointestinal stromal tumors by using bioinformatics approaches.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

7 hospitals in Zhengzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Zhengzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [The expression of neuraminidase-1 in Ewing sarcoma and its impact on sarcoma cell proliferation and migration].2023Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's SarcomaCompletedNCT05046314Study sitePhase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 222025

4 hospitals in Zhengzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceCAR-T & cell therapy
Papers it led5
  1. Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy.2025Frontiers in immunologyFree full text
  2. Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms.2025Seminars in diagnostic pathology
  3. High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.2023Discovery medicine
  4. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.2023Leukemia & lymphoma
  5. Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era.2021MedicineFree full text
Chinese-language papers (not in the count)4
  1. [The Value of sFLC and Serum Calcium in the Diagnosis and Prognosis of Multiple Myeloma Patients].2024Zhongguo shi yan xue ye xue za zhi
  2. [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients].2024Zhonghua yi xue za zhi
  3. [The significance of bone marrow immature plasma cell burden in the prognosis of newly diagnosed multiple myeloma patients].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Clinical and biological characteristics and prognosis of patients with biclonal multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

8 hospitals in Zhengzhou for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led2
  1. The prediction of haemophilic arthropathy progression based on MRI findings and clinical characteristics.2025Orphanet journal of rare diseases
  2. Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients.2023Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Earlier papers (2016–2020)3
  1. Multislice spiral computed tomography imaging in evaluating hemophilic arthropathy.2020Chinese medical journal
  2. [Clinical study on factor Ⅷ inhibitor in children with hemophilia A].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  3. Using synovial volume measurement by MRI to evaluate the effect of 32P Radiation synovectomy on hemophilic arthropathy patients.2019Journal of X-ray science and technology
All its trials on ClinicalTrials.gov, any status7
  1. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  2. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With InhibitorStatus unknownNCT05487976Study sitePhase 3Start 2022-04
  3. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  4. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  5. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04061109Study sitePhase 3Start 2019-05
  6. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04
  7. Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia ACompletedNCT02634723Study siteStart 2015-12

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Zhengzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Zhengzhou for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Zhengzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosis
Departments in papersNeurology
Papers it led2
  1. Single-cell RNA sequencing reveals cell type-specific immune regulation associated with human neuromyelitis optica spectrum disorder.2024Frontiers in immunologyFree full text
  2. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Zhengzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic & complement drugsStandard immunotherapy
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 5 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025

2 hospitals in Zhengzhou for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGeneticsRevascularisation surgeryImaging & blood flow
Departments in papersNeurosurgeryNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Zhengzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led2
  1. Single-cell transcriptomics reveals cell type-specific immune regulation associated with anti-NMDA receptor encephalitis in humans.2022Frontiers in immunology
  2. Autoimmune-mediated secondary-parkinsonism presented with micrographia and cognitive impairment.2021Journal of neuroimmunology
Earlier papers (2016–2020)2
  1. Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis.2019Journal of neuroimmunology
  2. Anti-N-methyl-D-aspartate receptor encephalitis with lung adenocarcinoma.2016Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Zhengzhou for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 5 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

12 hospitals in Zhengzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

  2. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07121413

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led5
  1. Antidepressant intervention to possibly delay disease progression and frailty in elderly idiopathic pulmonary fibrosis patients: a clinical trial.2025Aging clinical and experimental research
  2. Potential function exploration of lncRNAs in idiopathic pulmonary fibrosis: insights from whole transcriptome sequencing data analysis.2025Clinics (Sao Paulo, Brazil)
  3. Integrative Analysis of Endothelial Cell Senescence-Related Genes in Idiopathic Pulmonary Fibrosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  4. Genetic association of telomere length, obesity and tobacoo smoking with idiopathic pulmonary fibrosis risk.2023BMC public health
  5. Contribution of Adiponectin/Carnitine Palmityl Transferase 1A-Mediated Fatty Acid Metabolism during the Development of Idiopathic Pulmonary Fibrosis.2022Oxidative medicine and cellular longevity
Earlier papers (2016–2020)3
  1. Research Advances on DNA Methylation in Idiopathic Pulmonary Fibrosis.2020Advances in experimental medicine and biology
  2. Downregulation of microRNA‑30a in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis patients.2018Molecular medicine reports
  3. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies.2018Respiration; international review of thoracic diseases
All its trials on ClinicalTrials.gov, any status5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  5. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Zhengzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Two new cases with the UBQLN2 gene mutation in Han Chinese.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Earlier papers (2016–2020)2
  1. Novel mutation in optineurin causing aggressive ALS+/-frontotemporal dementia.2019Annals of clinical and translational neurology
  2. A novel SETX gene mutation associated with Juvenile amyotrophic lateral sclerosis.2018Brain and behavior

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Zhengzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Zhengzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. Molecular Pathogenic Mechanisms of IgA Nephropathy Secondary to COVID-19 mRNA Vaccination.2024Kidney & blood pressure research
All its trials on ClinicalTrials.gov, any status4
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Zhengzhou for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution

2 hospitals in Zhengzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou

  3. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  3. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  4. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Zhengzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisRecruitingNCT07387549Study sitePhase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 2 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 3.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

3 hospitals in Zhengzhou for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab.2023Dermatitis : contact, atopic, occupational, drug
  2. Haplotype-based non-invasive prenatal diagnosis of recessive dystrophic epidermolysis bullosa via targeted capture sequencing of maternal plasma.2023The Journal of dermatology
Chinese-language papers (not in the count)1
  1. [Variation of COL7A1 gene in dystrophic epidermolysis bullosa pruriginosa].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)1
  1. [Genetic analysis of a child with recessive dystrophic epidermolysis bullosa due to compound heterozygous variants of (COL7A1 gene].2020Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Zhengzhou for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 3 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 5.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

2 hospitals in Zhengzhou for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

河南省人民医院

Henan Provincial People's Hospital

郑州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
People's Hospital of Zhengzhou University; Zhengzhou University People's Hospital; and Affiliated Provincial People's Hospital of Zhengzhou University; Heart Center of Henan Provincial People's Hospital; Henan Provincial People' Hospital; Affiliated People's Hospital of Zhengzhou University; Henan Provincial People's Hospital Affiliated to Zhengzhou University; and Henan Provincial People's Hospital

Suggest a correctionDownload the data